triple hormone receptor agonist retatrutide for obesity A review of an investigational drug retatrutide, a novel agent the treatment of | European Journal of Clinical Pharmacology Triple-Hormone-Receptor Agonist Retatrutide for... :

Both the STEP-1 and SURMOUNT-4 trials included the availability of RDN dietary counseling and recommendations to exercise 150 min/week during the treatment period, but with notable weight regain for most participants upon GLP-1 discontinuation without continued nutrition support [18,273]

However, vibration plate use is not recommended for individuals with recent injuries or surgeries, severely compromised joints, or macular degeneration

Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

While Wegovy has established a reliable foundation with average weight loss of 15% to 17%, and Mounjaro has pushed these boundaries to 22.5%, Retatrutide achieves an average of 24.2% over 48 weeks at its highest dose

Also avoiding heavy fat meals may help

Versus semaglutide, tirzepatide 10 and 15 mg were associated with numerically greater decreases in SBP (mmHg) and diastolic blood pressure (DBP, mmHg) (Table 2)